A New Target Emerges in the Fight Against Fatty Liver Disease
A comprehensive review in Liver International highlights the L-α-lysophosphatidylinositol/G protein-coupled receptor 55 (LPI/GPR55) axis as a pivotal driver in the progression of metabolic dysfunction-associated steatohepatitis (MASH), the advanced form of fatty liver disease. This signaling pathway, part of the broader endocannabinoidome, promotes hepatic lipid accumulation, inflammation, and fibrosis by affecting hepatocytes, Kupffer cells, and hepatic stellate cells. The review details how the enzyme MBOAT7 exacerbates steatosis by modifying LPI and discusses the recent FDA approvals of resmetirom and semaglutide for MASH treatment. It proposes that future therapeutic strategies should focus on developing liver-specific modulators of the LPI/GPR55 axis to effectively combat metabolic-associated liver disease while minimizing off-target effects.
Study Significance: This research identifies a novel molecular target for treating MASH, a condition with limited therapeutic options. For gastroenterologists and hepatologists, understanding the LPI/GPR55 axis provides a framework for developing next-generation, tissue-specific pharmacotherapies that could more precisely halt disease progression. This insight directly informs clinical trial design and future drug development strategies aimed at the growing global burden of metabolic liver disease.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
